In the agreement with CoreValve, Medtronic will pay $700 million plus additional payments contingent on the achievement of agreed upon milestones. Medtronic will acquire Ventor for $325 million.
CoreValve is the developer of a transcatheter, transfemoral aortic valve replacement product. Ventor is the developer of two cardiovascular technologies — a minimally invasive, surgical transapical technology and a next-generation percutaneous, transfemoral technology.
Read the Medtronic news release on the acquisition of CoreValve.
Read the Medtronic news release on the acquisition of Ventor Technologies.
